目的：探讨罗格列酮对2型糖尿病大鼠种植体周围血小板衍生生长因子-B （PDGF-B）的影响。方法：选用2月龄SD大鼠30只，随机分为正常种植组（G1）、糖尿病种植组(G2)和糖尿病种植罗格列酮干预组(G3)。糖尿病模型采用高糖高脂饮食加小剂量链脲佐菌素诱导建立；种植模型于大鼠胫骨近骺端植入1.3mm×5mm纯钛种植体；罗格列酮干预组每日灌胃给药。三组大鼠每周测定一次血糖，于12周时经双能X线骨密度仪测定大鼠全身骨密度，处死大鼠后收集右侧胫骨，胫骨经固定、脱钙后制成切片，常规苏木精-伊红染色( HE染色)，免疫组织化学法检测种植体周围骨组织中血小板衍生生长因子-B的表达情况。结果：正常组大鼠种植体周围血小板衍生生长因子-B的表达较多，糖尿病组次之，罗格列酮干预组表达最少；全身骨密度值的测量结果与免疫组化结果一致。结论：罗格列酮虽能降低2型糖尿病大鼠的血糖，但其对糖尿病大鼠骨组织有加重损害作用，其作用机制可能是通过抑制骨组织中血小板衍生生长因子-B的表达而完成的。%Objective: To investigate the effects of Rosiglitazon on PDGF-B in osseous tissue around implant of type 2 diabetic rats. Methods: Thirty two-month-old rats were randomly divided into three groups:normal implant group (G1), diabetic implant group (G2) and diabetic implant group with Rosiglitazon intervention (G3). The diabetic modal was founded by feeding high-glucose-high-fat diet and injecting low dose streptozotocin (STZ). The implant modal was founded by inserting the titanium implant whose diameter is 1.3mm and length is 5mm in the right tibia near the epiphseal end. The intervention group was fed Rosiglitazon by rat`s stomach. 12 weeks later, the rats bone mineral density were measured, then the rats were killed and taken the right tibia. The hard tissue was fixed, decalcified and sectioned with conventional HE staining and immunohistochemistry to detect the expression of PDGF-B around implant. Results: The PDGF-B expression of normal is intense, PDGF-B expression of diabetic group is less, but, the intervention group is the least. The results of bone mineral density are consistent with the results of immunohistochemistry. Conclusion: Rosiglitazon can decrease blood glucose of diabetic rat, however, is bad for the bone tisse, its mechanism is likely to suppress the PDGF-B expression of bone tisse to achieve the perniciasm.
展开▼
